Last reviewed · How we verify

NCT03126409

No-Touch Versus Conventional Saphenous Vein Harvesting Technique

Active, enrolled NA Last updated 4 October 2024
What this trial tests

NA trial testing No-Touch vein harvesting technique in Coronary Artery Disease in 2,655 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
14 May 2017
Primary endpoint
30 December 2029
30 December 2029

Quick facts

Lead sponsorChina National Center for Cardiovascular Diseases
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment2,655
Start date14 May 2017
Primary completion30 December 2029
Estimated completion30 December 2029
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

18 and older, any sex, with Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the short-term patency of vein graft harvested by the No-Touch technique compared to that by the conventional approach in patients undergoing isolated on-pump/off-pump coronary artery bypass graft (CABG) surgery. a total of at least 2000 patients undergoing isolated on-pump/off-pump CABG will be consecutively recruited from 7 hospitals across China and randomly assigned to receive No-Touch saphenous vein harvesting or conventional approach. All participants will be invited for clinical follow-up and 64-slice multislice computed tomography angiography (MSCTA) analysis at 3 months post-operatively.

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

  1. SUPERIOR SVG: no touch saphenous harvesting to improve patency following coronary bypass grafting (a multi-Centre randomized control trial, NCT01047449).
    Deb S, Singh SK, de Souza D, Chu MWA, et al · · 2019 · cited 86× · PMID 31046806 · DOI 10.1186/s13019-019-0887-x
  2. No-Touch Versus Conventional Vein Harvesting Techniques at 12 Months After Coronary Artery Bypass Grafting Surgery: Multicenter Randomized, Controlled Trial.
    Tian M, Wang X, Sun H, Feng W, et al · · 2021 · cited 80× · PMID 34510911 · DOI 10.1161/circulationaha.121.055525
  3. Twenty-Five Years of No-Touch Saphenous Vein Harvesting for Coronary Artery Bypass Grafting: Structural Observations and Impact on Graft Performance.
    Samano N, Souza D, Pinheiro BB, Kopjar T, et al · · 2020 · cited 26× · PMID 32270965 · DOI 10.21470/1678-9741-2019-0238
  4. The evolving evidence base for coronary artery bypass grafting and arterial grafting in 2021: How to improve vein graft patency.
    Vervoort D, Malik A, Fremes SE. · · 2021 · cited 13× · PMID 34977712 · DOI 10.1016/j.xjtc.2021.09.038
  5. Stable Hemodynamics within "No-Touch" Saphenous Vein Graft.
    Jiang Q, Yang Y, Sun H, Tang Y, et al · · 2020 · cited 11× · PMID 31611499 · DOI 10.5761/atcs.oa.19-00156
  6. No-touch versus conventional vein in coronary artery bypass grafting: three year follow-up of multicentre randomised PATENCY trial.
    Tian M, Wang X, Feng W, Wang H, et al · · 2025 · cited 6× · PMID 40306935 · DOI 10.1136/bmj-2024-082883
  7. Graft patency of no-touch versus conventionally harvested saphenous vein conduits in coronary artery bypass grafting: A frequentist and Bayesian meta-analysis of randomized trials.
    Deng MX, Li Z, Vervoort D, Evan RN, et al · · 2025 · PMID 40309673 · DOI 10.1016/j.xjon.2025.02.007

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03126409.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing